search
Back to results

Treatment and Outcome of Early Onset Bipolar Disorder

Primary Purpose

Bipolar Disorder

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Lithium
Olanzapine
Divalproex
Risperidone
Quetiapine
Ziprasidone
Aripriprazole
Sponsored by
Northwell Health
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Disorder focused on measuring Adolescence

Eligibility Criteria

10 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: Have a diagnosis of Bipolar I Disorder; Have had aggressive and/or psychotic features (delusions, hallucinations and/or thought disorder) during the most recent manic episode; Is willing to be treated or is already being treated with the combination of mood stabilizer(s) (lithium or Depakote) and an atypical antipsychotic medication (Abilify, Geodon, Risperdal, Seroquel, or Zyprexa); Live in the NY Metropolitan area; Able to attend weekly to biweekly office visits Exclusion Criteria: Medical contraindication to treatment with lithium and divalproex Seizure disorder Pregnancy Unwillingness to use acceptable methods of birth control if sexually active IQ less than 70 Substance-induced mood disorder or mood disorder due to a general medical condition Prior experience with re-emergence of psychotic features or severe aggression within 6 months of antipsychotic medication discontinuation under circumstances similar to those in the study Potentially lethal suicide attempts or infliction of serious injury upon someone during most severe bipolar episode High risk for running away or truancy

Sites / Locations

  • The Zucker Hillside Hospital, Long Island Jewish Medical Center

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 8, 2002
Last Updated
January 21, 2014
Sponsor
Northwell Health
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00048802
Brief Title
Treatment and Outcome of Early Onset Bipolar Disorder
Official Title
Treatment and Outcome of Early Onset Bipolar Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
August 2002 (undefined)
Primary Completion Date
August 2006 (Actual)
Study Completion Date
August 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Northwell Health
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

5. Study Description

Brief Summary
This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
Detailed Description
In children and adolescents, bipolar disorder is often accompanied by symptoms such as hallucinations, delusions, or paranoia that require acute treatment with a combination of an atypical antipsychotic medication and a mood stabilizer. It is not known if it is necessary to continue treatment with the atypical antipsychotic medication after the child's symptoms have remitted. Participants in this study are treated with lithium, divalproex (Depakote), and one of the following atypical antipsychotic medications: olanzapine (Zyprexa), risperidone (Risperdal) or quetiapine (Seroquel) for at least 24 weeks. Participants who have already begun combination therapy with at least one of the mood stabilizers and atypical antipsychotic medications listed above are also encouraged to enroll in this study. After participants have been on combination therapy for at least 24 weeks they will then be randomly assigned to one of two groups. The first group will continue to receive active mood stabilizer and atypical antipsychotic medication. The second group will receive active mood stabilizer and placebo. Participants are assessed weekly and followed for up to 18 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder
Keywords
Adolescence

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
40 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Lithium
Intervention Type
Drug
Intervention Name(s)
Olanzapine
Intervention Type
Drug
Intervention Name(s)
Divalproex
Intervention Type
Drug
Intervention Name(s)
Risperidone
Intervention Type
Drug
Intervention Name(s)
Quetiapine
Intervention Type
Drug
Intervention Name(s)
Ziprasidone
Intervention Type
Drug
Intervention Name(s)
Aripriprazole

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Have a diagnosis of Bipolar I Disorder; Have had aggressive and/or psychotic features (delusions, hallucinations and/or thought disorder) during the most recent manic episode; Is willing to be treated or is already being treated with the combination of mood stabilizer(s) (lithium or Depakote) and an atypical antipsychotic medication (Abilify, Geodon, Risperdal, Seroquel, or Zyprexa); Live in the NY Metropolitan area; Able to attend weekly to biweekly office visits Exclusion Criteria: Medical contraindication to treatment with lithium and divalproex Seizure disorder Pregnancy Unwillingness to use acceptable methods of birth control if sexually active IQ less than 70 Substance-induced mood disorder or mood disorder due to a general medical condition Prior experience with re-emergence of psychotic features or severe aggression within 6 months of antipsychotic medication discontinuation under circumstances similar to those in the study Potentially lethal suicide attempts or infliction of serious injury upon someone during most severe bipolar episode High risk for running away or truancy
Facility Information:
Facility Name
The Zucker Hillside Hospital, Long Island Jewish Medical Center
City
Glen Oaks
State/Province
New York
ZIP/Postal Code
11004
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11765291
Citation
Kafantaris V, Coletti DJ, Dicker R, Padula G, Kane JM. Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatry. 2001 Dec;40(12):1448-56. doi: 10.1097/00004583-200112000-00016.
Results Reference
background
PubMed Identifier
7608046
Citation
Kafantaris V. Treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995 Jun;34(6):732-41. doi: 10.1097/00004583-199506000-00013.
Results Reference
background
PubMed Identifier
12960703
Citation
Kafantaris V, Coletti D, Dicker R, Padula G, Kane JM. Lithium treatment of acute mania in adolescents: a large open trial. J Am Acad Child Adolesc Psychiatry. 2003 Sep;42(9):1038-45. doi: 10.1097/01.CHI.0000070247.24125.24.
Results Reference
background

Learn more about this trial

Treatment and Outcome of Early Onset Bipolar Disorder

We'll reach out to this number within 24 hrs